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Myocarditis remains a challenging diagnosis that arises from a
range of potential insults that can result in cardiac inﬂamma-
tion, immune activation and functional impairment [1]. Acute
viral infection represents the leading aetiology followed by drug-
induced hypersensitivity, giant cell myocarditis and cardiac
involvement in systemic autoimmune disease [2]. Due to hetero-
geneity in clinical presentation and disease severity, accurate
epidemiological assessment is limited but overall prevalence is
estimated at 22 cases per 100 000 patients annually [3]. Clozapine
is the cornerstone of therapy in refractory schizophrenia and sig-
niﬁcantly reduces suicide rates further than other antipsychotic
agents [4]. However, cardiotoxicity resulting in myocarditis can
occur in 1–3% of patients and can result in complications includ-
ing sudden cardiac death and heart failure [5, 6].
The case report by Datta and Solomon [7] describes a young
patient presenting acutely with chest pain, ST segment elevation
and mild troponin level elevation. Following the demonstration
of unobstructed coronary arteries on invasive angiography and
impaired left ventricular function on transthoracic echocardi-
ography, a diagnosis of myocarditis likely secondary to cloza-
pine was reached. This report emphasizes the need for prompt
recognition of myocarditis and immediate withdrawal of ther-
apy where clozapine-induced myocarditis is suspected. These
features appeared 2 days after starting clozapine therapy.
However, it should be noted that symptoms are often non-
speciﬁc with chest pain occurring in only half of all cases and
clinical presentation varying between Days 14 and 21 after
therapy initiation [8, 9]. In some cases, presentations may
indeed be delayed by several months requiring a high degree
of clinical suspicion for diagnosis [10].
At present, the gold standard for diagnosis of myocarditis
remains an endomyocardial biopsy [11]. Histopathological ana-
lysis with immunostaining conﬁrms the presence and charac-
terizes the nature of acute inﬂammatory inﬁltrates. However,
the limitations of endomyocardial biopsy are many and include
high rates of sampling error, interobserver variability and peri-
procedural risks of cardiac tamponade and death. For these
reasons, endomyocardial biopsy is rarely a practical ﬁrst step in
the diagnosis of myocarditis in the majority of centres.
Cardiovascular magnetic resonance imaging (CMR) has
emerged as an important diagnostic tool for the non-invasive
assessment of acute myocarditis. Standard myocardial tissue
characterization techniques can detect myocardial oedema,
reactive hyperaemia and replacement ﬁbrosis from myocyte
cell death [12]. Diagnostic accuracy is further enhanced with
novel T1 and T2 mapping approaches as shown in Fig. 1 [13].
CMR also plays an equally important role in the exclusion of
other causes of troponin-positive chest pain and unobstructed
coronary arteries, such as infarction due to recanalisation,
spasm or embolism [14]. However, access to CMR is often lim-
ited and may be impractical as a screening test in all patients.
Circulating biomarkers of myocardial injury, such as troponin,
represent a more feasible initial investigation and possible
approach for routine interval screening, which is relevant given
that clinical presentation can be non-speciﬁc [9].
Multiple potential mechanisms have been proposed for
clozapine-induced myocarditis [5]. Hypersensitivity eosino-
philic myocarditis is well documented with antibiotics (37%),
central nervous system agents (21%, primarily clozapine fol-
lowed by carbamazepine), vaccines (8%) and a range of other
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agents in 33% [15]. An alternative mechanism may be linked to
increased circulating noradrenaline levels, which may result in
cardiac dysfunction [16]. This form of acute ‘catecholaminergic’
myocarditis is difﬁcult to distinguish from Takotsubo cardio-
myopathy but are still considered distinct entities [17]. However,
it should be remembered that aetiology may be confounded by
concomitant illicit drug use, and that both external insults may
act synergistically to cause myocarditis.
Clozapine re-challenge after an episode of acute myocarditis
remains an unanswered question. Given the limited alternative
therapeutic options in this group of patients, further investiga-
tion may be helpful alongside approaches at more intensive
monitoring when initiating clozapine therapy that may include
high-sensitivity troponin assays and CMR, although under-
standably many physicians and psychiatrists are hesitant.
In summary, clozapine-induced myocarditis remains a rare
but potentially fatal complication and this case emphasizes the
need for pharmaco-vigilance, early recognition of myocarditis
and the need for deﬁnitive diagnosis by endomyocardial biopsy
or CMR.
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